Logo
x

Search

Subscribe Now

ACADIA

PharmaShots Weekly Snapshots (April 22 – April 26, 2024)

PharmaShots Weekly Snapshots (April 22 – April 26, 2024)

  • April 26, 2024
Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome

Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome

  • April 23, 2024
Acadia Expands its License Agreement with Neuren to Acquire Ex-North American Rights to Trofinetide and Global Rights to NNZ-2591

Acadia Expands its License Agreement with Neuren to Acquire Ex-North American Rights to Trofinetide and Global Rights to NNZ-2591

  • July 14, 2023
Insights+: The US FDA New Drug Approvals in March 2023

Insights+: The US FDA New Drug Approvals in March 2023

  • April 19, 2023
Acadia Reports the NDA Submission of Trofinetide to the US FDA for the Treatment of Rett Syndrome

Acadia Reports the NDA Submission of Trofinetide to the US FDA for the Treatment of Rett Syndrome

  • July 19, 2022
Acadia Collaborated with Stoke to Develop and Commercialize RNA-Based Therapies for Rare Genetic Neurodevelopmental Diseases

Acadia Collaborated with Stoke to Develop and Commercialize RNA-Based Therapies for Rare Genetic Neurodevelopmental Diseases

  • January 11, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.